MorphoSys AG - American Depositary Shares (NQ:MOR)

18.96 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MorphoSys AG - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

MorphoSys AG Reports First Quarter 2022 Financial Results

May 04, 2022

From MorphoSys AG

Via Business Wire

Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022

April 28, 2022

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

From MorphoSys AG

Via AccessWire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 24, 2022

Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV) shares moved upwards by 55.5% to $2.13 during Thursday's pre-market session. The market value of their outstanding...

Via Benzinga

The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale ↗

March 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland ↗

March 23, 2022

The

Via Benzinga

MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL

March 22, 2022

MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell...

From MorphoSys AG

Via AccessWire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 22, 2022

Gainers Palisade Bio (NASDAQ:PALI) stock rose 59.0% to $1.28 during Tuesday's pre-market session. The company's market cap stands at $23.3 million. As per the news...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

March 22, 2022

Grab your cup of coffee, investor! We're starting off the day with a dive into the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

March 16, 2022

From MorphoSys AG

Via Business Wire

Earnings Scheduled For March 16, 2022 ↗

March 16, 2022

Companies Reporting Before The Bell • Ideanomics (NASDAQ:IDEX) is likely to report quarterly loss at $0.05 per share on revenue of $33.20 million. • Tarena...

Via Benzinga

National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas

March 15, 2022

BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network(R) (NCCN)...

From MorphoSys AG

Via AccessWire

Earnings Outlook For MorphoSys ↗

March 15, 2022

MorphoSys (NASDAQ:MOR) is set to give its latest quarterly earnings report on Wednesday, 2022-03-16. Here's what investors need to know before the announcement. Analysts estimate...

Via Benzinga

Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022

March 10, 2022

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR);(NASDAQ:MOR) will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm...

From MorphoSys AG

Via AccessWire

MorphoSys Discontinues US Discovery Activities, Takes €231M Impairment Charge ↗

March 10, 2022

MorphoSys AG (NASDAQ: MOR) has reported a non-cash impairment charge of €231 million on goodwill after consolidating research and discovery functions. This...

Via Benzinga

MorphoSys AG Reports Non-Cash Impairment Charge of € 231 Million on Goodwill After Consolidation of Research and Discovery Functions; Corresponding Increase of Group Operating Expenses in 2021

March 10, 2022

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR)...

From MorphoSys AG

Via AccessWire

MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report

January 24, 2022

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 24, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) was acknowledged as a Best Practice Leader in the European Women on Boards' Gender Equality Index Report,...

From MorphoSys AG

Via AccessWire

Stocks That Hit 52-Week Lows On Friday ↗

February 18, 2022

On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

February 17, 2022

On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company...

Via Benzinga

MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance

January 18, 2022

- Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million ( € 66.9 million) - Anticipated 2022 Monjuvi U.S. net product sales in the range of US$ 110 to 135 million PLANEGG / MUNICH,...

From MorphoSys AG

Via AccessWire

Benzinga's Top Ratings Upgrades, Downgrades For January 14, 2022 ↗

January 14, 2022

Upgrades According to Seaport Global, the prior rating for Lennar Corp (NYSE:

Via Benzinga

MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference

January 10, 2022

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / Janauary 10, 2022 / MorphoSys AG (FSE:MOR; NASDAQ:MOR), announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40...

From MorphoSys AG

Via AccessWire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

January 06, 2022

Gainers Freeline Therapeutics (NASDAQ:FRLN) stock increased by 58.1% to $3.1 during Thursday's pre-market session. The company's market cap stands at $111.0...

Via Benzinga

20 Stocks Moving in Wednesday's Pre-Market Session ↗

December 22, 2021

Gainers BioRestorative Therapies, Inc. (NASDAQ: BRTX) rose 48.1% to $6.77 in pre-market trading after the company entered into a Master Service Agreement with PRC Clinical,...

Via Benzinga

MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis

December 12, 2021

MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis - Data presented during poster and oral sessions at the 63rd...

From MorphoSys AG

Via AccessWire

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

December 11, 2021

- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies - Results from the retrospective cohort analysis indicate...

From MorphoSys AG

Via AccessWire

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

December 11, 2021

From Incyte

Via Business Wire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 10, 2021

Gainers Reshape Lifesciences (NASDAQ:RSLS...

Via Benzinga

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

Corporate Calendar 2022

November 29, 2021

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 29, 2021 / Corporate Calendar 2022 Dear Madam/Sir, Please note MorphoSys' financial reporting dates 2022 as follows: Publication of Interim Statement /...

From MorphoSys AG

Via AccessWire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 22, 2021

Gainers iSpecimen (NASDAQ:ISPC) stock rose 31.09% to $6.45 during Monday's pre-market session. The company's market cap stands at $44.9 million. Provention Bio (...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.